Proglucagon-derived peptides: human physiology and therapeutic potential
Physiological Reviews · 01.01.2026 · 106 (1) · 529-586
DOI: 10.1152/physrev.00057.2024 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Physiological Reviews, erschienen am 01.01.2026. Verfasst von Lærke S Gasbjerg und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Metabolic Research, Herlev and Gentofte University Hospital, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Proglucagon. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 591 Literaturangaben.
Abstract (Originalsprache)
Proglucagon-derived peptides represent a class of peptide hormones derived from the proglucagon precursor. These peptides, including glucagon, glucagon-like peptide 1 (GLP-1), glucagon-like peptide 2 (GLP-2), and oxyntomodulin, exert diverse effects on several aspects of human physiology, ranging from glucose, lipid, and protein metabolism to appetite regulation, nutrient absorption, and gastrointestinal motility. Their actions are mediated by distinct G protein-coupled receptors, influencing endocrine, neuroendocrine, and metabolic processes, and over recent decades the proglucagon-derived peptides have emerged as central players in the management of metabolic and gastrointestinal diseases. Glucagon has long been recognized for its role in treating hypoglycemia, whereas GLP-1 receptor agonists have revolutionized the treatment of type 2 diabetes and obesity because of their glucose-lowering, appetite-suppressing, and cardiovascular protective effects. GLP-2 analogs offer targeted therapy for short bowel syndrome, addressing critical needs in this nutrient malabsorptive condition. This clinical review provides an exploration of the human physiology of the proglucagon-derived peptides, their involvement in pathophysiology, and their therapeutic applications. We discuss advancements in mono- and multireceptor agonists from a clinical perspective that leverage combined actions and explore future perspectives, including novel indications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Clinical Metabolic Research, Herlev and Gentofte University Hospital, Copenhagen, Denmark.
- Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Novo Nordisk A/S, Søborg, Denmark.
- Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Department of Transplantation and Digestive Diseases, Section of Intestinal Failure, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
ORCID-Profile: Lærke S Gasbjerg, Casper K Nielsen, Jens J Holst, Asger B Lund
Zitieren
APA
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. B. (2026). Proglucagon-derived peptides: human physiology and therapeutic potential. Physiological Reviews, 106(1), 529-586. https://doi.org/10.1152/physrev.00057.2024
Vancouver
Gasbjerg LS, Nielsen CK, Suppli MP, Grøndahl MFG, Holst JJ, Knop FK, et al. Proglucagon-derived peptides: human physiology and therapeutic potential. Physiological Reviews. 2026;106(1):529-586. doi:10.1152/physrev.00057.2024
BibTeX
@article{Gasbjerg2026,
author = {Gasbjerg, Lærke S and Nielsen, Casper K and Suppli, Malte P and Grøndahl, Magnus F G and Holst, Jens J and Knop, Filip K and Jeppesen, Palle B and Lund, Asger B},
title = {Proglucagon-derived peptides: human physiology and therapeutic potential},
journal = {Physiological Reviews},
year = {2026},
volume = {106},
number = {1},
pages = {529--586},
doi = {10.1152/physrev.00057.2024}
}
EUVIMED